 |
Chair:
Elizabeth Manias RN, BPharm, MPharm, MNStud, PhD, FRCNA, MPS,
Professor, Associate Head of Research, Melbourne School of Health Sciences,
Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne,
Carlton, Victoria, Australia
|
Leadership Group:
Allison Williams PhD, RN Senior Research Fellow, Melbourne School of Health Sciences, Carlton, Australia
Andrew Peterson PhD, BS, PharmD, Interim Dean, Mayes College of Healthcare Business and Policy, University of the Sciences in Philadelphia, PA
Anthony Udezi PharmD, Lecturer, University of Benin, Nigeria
Anuja Roy MBA, MSc Senior Manager, Global Health Economics & Outcomes Research, Takeda Pharmaceuticals International, Inc,
Deerfield IL, USA
Craig Roberts PharmD, MBA, Senior Director, Outcomes Research, Pfizer Inc, New York, USA
David Hutchins BS, MBA, MHA, Senior Advisor, Strategic Analytics R&D, Caremark, Scottsdale, AZ, USA
Dyfrig Hughes PhD, MSc, Reader in Pharmacoeconomics, Bangor University Centre for Economics and Policy in Health, IMSCaR, Bangor, Wales, UK
Ian Barron PhD, PharmD, Research Fellow, University of Dublin, Trinity College Department of Pharmacology & Therapeutics, Dublin, Ireland
John Zeber PhD, MHA, Investigator / Assistant Professor, Veterans Affairs HSRD, San Antonio, TX, USA
Rose Mullen PhD, MBA, RN, Outcome Liaison, Eli Lilly, Westfield, IN, USA
Stacey Guy BSocSci, Hons Psych, Masters Psych, Research Assistant, I-THINK Research Lawson Health Research Institute, 801 Commissioners Rd E, Suite B3041, London, Ontario, Canada
Vernon Schabert PhD, BA, Principal, Health Economics and Outcomes Research IMS Health, Santa Barbara, CA, USA
Objectives:
Develop standards for analyses of medication compliance and treatment persistence and their relationship to health outcomes.
Activities:
- Defining non‐compliance: re‐examining the 80% threshold and refill gaps
Description: An arbitrary cut‐off of 80% may not adequately characterize patient behavior. Incorporating the pharmacokinetic and dynamic profile of the drug is equally important as is the disease being treated.
Project Leader: Femida Gwadry‐Sridhar Proposed methodology:
1) Examining the limitations of the 80% threshold by looking at a 60‐90% variation. The threshold’s impact on clinical importance will be studied using examples of different drug classes with different properties.
2) This data will then be used to simulate clinical outcomes based on different thresholds.
3) We will then illustrate the importance of refill gaps in therapy as an additional metric affecting clinical outcomes. The timing and frequency of refill gaps will also be considered.
Project start date: May 2010
- Initial compliance: rates & variables influencing initial compliance
Description: What are the rates of initial compliance to medications? What variables influence a patient’s willingness to take a medication for the first time?
Project Leader: Andrew Peterson
Proposed methodology:
Comprehensive review of initial medication compliance studies. Search strategies to identify controlled trials measuring initial compliance will be developed. From this, areas of research and potential methodologies will be identified and discussed.
Project start date: In Progress
- Issues in Compliance Paper
Submitted for publication to the “British Journal of Clinical Pharmacology.
Objective: to provide guidance to researchers and clinicians who seek to measure, analyze, and interpret medication compliance and persistence obtained from pharmacy claims data.
Methodology of paper: Literature review conducted of articles that involved measurement of compliance, adherence or persistence. Measures were excluded if they were insufficiently described or produced non-numeric values.
Description of paper: Recommendations for ratio-based measures of medication compliance or gaps
Recommendations for duration-based measures of medication compliance
Validation of measures
Interpretation and application of patient compliance data
Continuous vs. dichotomous (categorical) compliance response and analytic rigor.
|
